Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neoadjuvant Melanoma Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Melanoma
Interventions
Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System
Drug · Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced May 21, 2026, 11:58 PM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Therapeutic Conventional Surgery
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
817
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 512 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 21, 2026, 11:58 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Cutaneous Melanoma
Interventions
Pembrolizumab, Talimogene Laherparepvec
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced May 21, 2026, 11:58 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
Interventions
Nivolumab, Nivolumab + Relatlimab, Ipilimumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced May 21, 2026, 11:58 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Malignant Melanoma Stage III
Interventions
Neoadjuvant ipilimumab + nivolumab, Adjuvant nivolumab
Drug
Lead sponsor
The Netherlands Cancer Institute
Other
Eligibility
16 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced May 21, 2026, 11:58 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID
Interventions
Daromun, Surgery, Adjuvant therapy
Drug · Procedure
Lead sponsor
Philogen S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
19
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced May 21, 2026, 11:58 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, HF10
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 12, 2022 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Melanoma
Interventions
Vemurafenib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced May 21, 2026, 11:58 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Darovasertib, Primary Local Therapy
Drug · Procedure
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
35
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 21, 2026, 11:58 PM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC, HPV-associated Cancers, Neoadjuvant Melanoma, Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)
Interventions
TransCon TLR7/8 Agonist, Pembrolizumab
Drug
Lead sponsor
Ascendis Pharma Oncology Division A/S
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
17
States / cities
Duarte, California • Los Angeles, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Melanoma, Malignant Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
Interventions
therapeutic conventional surgery, laboratory biomarker analysis, Axitinib, pharmacological study
Procedure · Other · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced May 21, 2026, 11:58 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
Interventions
TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery, Trastuzumab, Trastuzumab emtansine (T-DM1)
Drug · Procedure
Lead sponsor
Ascendis Pharma Oncology Division A/S
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
14
States / cities
Los Angeles, California • Springfield, Illinois • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Vibostolimab, Gebasaxturev, MK-4830, Favezelimab + Pembrolizumab, ATRA
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced May 21, 2026, 11:58 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Interventions
Dabrafenib, Spartalizumab, Therapeutic Conventional Surgery, Trametinib
Drug · Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced May 21, 2026, 11:58 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Pathologic Stage III Cutaneous Melanoma AJCC v8
Interventions
Imprime PGG, Pembrolizumab
Biological
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
La Jolla, California • Whittier, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced May 21, 2026, 11:58 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV
Interventions
Nivolumab, BMS-986205, Ipilimumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced May 21, 2026, 11:58 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Melanoma, Melanoma Stage III
Interventions
PET Scan, Nivolumab, Ipilimumab, Surgical Resection of Melanoma
Diagnostic Test · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced May 21, 2026, 11:58 PM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Melanoma
Interventions
ipilimumab
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced May 21, 2026, 11:58 PM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Melanoma
Interventions
T-Vec
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced May 21, 2026, 11:58 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Cervical Carcinoma, Esophageal Carcinoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck, Oral Cavity Mucosal Melanoma, Recurrent Melanoma, Stage II Vulvar Cancer AJCC v7, Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7, Stage IIIC Vulvar Cancer AJCC v7, Stage IV Oral Cavity Cancer AJCC v6 and v7, Stage IV Vulvar Cancer AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Vaginal Carcinoma
Interventions
Conventional Surgery, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Patient Observation, Radiation Therapy
Procedure · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma
Interventions
Talimogene Laherparepvec, Immediate surgical resection of melanoma lesion(s)
Drug · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
22
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced May 21, 2026, 11:58 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Darovasertib
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
10
States / cities
Scottsdale, Arizona • La Jolla, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced May 21, 2026, 11:58 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Melanoma
Interventions
administration of ipilimumab10mg/kg, administration of ipilimumab 3mg/kg + HDI
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced May 21, 2026, 11:58 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Stage IIIB-C Melanoma
Interventions
Vemurafenib and Cobimetinib
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced May 21, 2026, 11:58 PM EDT